Treatment of Ectopic Calcification in Fahr's Disease or Syndrome
Status:
Not yet recruiting
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
Fahr's disease or syndrome are neurodegenerative diseases in which patients present with
bilateral vessel associated calcifications in the basal ganglia. The clinical penetration of
Fahr's disease or syndrome is incomplete and heterogeneous comprising of neuropsychiatric
signs, cognitive decline, movement disorders, and various other signs (migraine, speech
disorders, pain, seizures). The symptoms start between 30 and 50 years and are (slowly)
progressive. Symptomatic patients have an increased risk for dependence in activities of
daily living and impaired quality of life.
Currently, disease-modifying therapies are not available for patients with Fahr's disease or
syndrome. However, in a small case series it was shown that alendronate was effective in the
clinical treatment of several patients with Fahr's disease or syndrome. Now the time has come
to investigate the effectiveness of treatment with bisphosphonates in patients with Fahr's
disease or syndrome in a randomized controlled trial.